Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMihaly Hajos, PharmD, PhD
Professor AdjunctAbout
Copy Link
Titles
Professor Adjunct
Biography
Mihaly Hajos is a Professor Adjunct at the Section of Comparative Medicine, leading the Laboratory of Translational Neuropharmacology. He received a Pharm.D. degree from Albert Szent-Gyorgyi Medical University, Szeged, Hungary, and a Ph.D. from University of Goteborg, Sweden. His research interest includes neurobiology and pharmacology of psychiatric and neurological disorders, application of systems electrophysiology in drug discovery, and translational aspects of neurophysiological measures from preclinical to clinical studies.
Appointments
Comparative Medicine
Professor AdjunctPrimary
Other Departments & Organizations
- All Institutions
- Comparative Medicine
Education & Training
- PhD
- University of Goteborg, Pharmacology, Medical School
- PharmD
- A. Szent-Gyorgyi Medical University, Physiology and Pathophysiology
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-5379-8576
Research at a Glance
Yale Co-Authors
Publications Timeline
Tamas Horvath, DVM, PhD
Milan Stoiljkovic, MD, PhD
Deepak Cyril Dsouza, MBBS, MD
Publications
2025
Spectris TM non‐invasive neuromodulation in Alzheimer’s disease
Kern R, Lee L, Zusterzeel R, Konisky A, Hempel E, Leach J, Seshagiri C, Hajos M, Howell C. Spectris TM non‐invasive neuromodulation in Alzheimer’s disease. Alzheimer's & Dementia 2025, 21: e100579. PMCID: PMC12740528, DOI: 10.1002/alz70859_100579.Peer-Reviewed Original ResearchCitationsSensory evoked gamma oscillation reduces white matter loss and preserves myelin in Alzheimer's disease: neuroimaging and proteomics findings
Hajos M. Sensory evoked gamma oscillation reduces white matter loss and preserves myelin in Alzheimer's disease: neuroimaging and proteomics findings. Alzheimer's & Dementia 2025, 21: e097702. PMCID: PMC12734711, DOI: 10.1002/alz70856_097702.Peer-Reviewed Original ResearchSpectrisTM combined audiovisual sensory stimulation elicits stronger EEG brain response than auditory or visual stimulation alone
Seshagiri C, Jackson B, Hernandez M, Leach J, Kern R, Boasso A, Hajos M. SpectrisTM combined audiovisual sensory stimulation elicits stronger EEG brain response than auditory or visual stimulation alone. Alzheimer's & Dementia 2025, 21: e107772. PMCID: PMC12788959, DOI: 10.1002/alz70856_107772.Peer-Reviewed Original ResearchTime saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
Kern R, Haaland B, Nicodemus‐Johnson J, Dickson S, Morgan M, Christensen J, Sabbagh M, Lee L, Hajós M, Riddle J, Seshagiri C, Howell C, Mallinckrodt C, Hendrix S. Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70118. PMID: 40501511, PMCID: PMC12152371, DOI: 10.1002/trc2.70118.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWhole-brain volumeMini-Mental State ExaminationOpen-label extensionMild to moderate ADEvoked gamma oscillationsGamma oscillationsADCS-ADLActivities of daily livingWhole-brain atrophyPost Hoc AnalysisMeasures of whole-brain volumeMini-MentalState ExaminationAlzheimer's Disease Cooperative Study-ActivitiesAlzheimer's diseaseMonths of active treatmentDaily livingActive treatmentRandomized controlled trial phaseOpen-label extension phaseModerate Alzheimer's diseaseWhole-brain volume changesEffect of active treatmentMonths of progressionMemory consolidationA novel method for harmonization of PET image spatial resolution without phantoms
Carbonell F, Zijdenbos A, Hempel E, Hajós M, Bedell B. A novel method for harmonization of PET image spatial resolution without phantoms. EJNMMI Physics 2025, 12: 23. PMID: 40082316, PMCID: PMC11906943, DOI: 10.1186/s40658-025-00740-9.Peer-Reviewed Original ResearchCitationsConceptsPhantom imagesGroup of imagesLinear regression problemSpatial resolutionAlzheimer's Disease Neuroimaging InitiativeRegression problemPET imagingHoffman phantomResolution estimatesEstimation of spatial resolutionMultiple linear regression problemFourier domainImage spatial resolutionPhysical phantomAcquisition of imagesMaximum difference valuePhantom dataPhantomReconstruction parametersScanner modelsIn-planeVoxel sizeFourier transformSubject's PET imageIntensity plotsAlpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true?
Babiloni C, Arakaki X, Baez S, Barry R, Benussi A, Blinowska K, Bonanni L, Borroni B, Bayard J, Bruno G, Cacciotti A, Carducci F, Carino J, Carpi M, Conte A, Cruzat J, D'Antonio F, Della Penna S, Del Percio C, De Sanctis P, Escudero J, Fabbrini G, Farina F, Fraga F, Fuhr P, Gschwandtner U, Güntekin B, Guo Y, Hajos M, Hallett M, Hampel H, Hanoğlu L, Haraldsen I, Hassan M, Hatlestad-Hall C, Horváth A, Ibanez A, Infarinato F, Jaramillo-Jimenez A, Jeong J, Jiang Y, Kamiński M, Koch G, Kumar S, Leodori G, Li G, Lizio R, Lopez S, Ferri R, Maestú F, Marra C, Marzetti L, McGeown W, Miraglia F, Moguilner S, Moretti D, Mushtaq F, Noce G, Nucci L, Ochoa J, Onorati P, Padovani A, Pappalettera C, Parra M, Pardini M, Pascual-Marqui R, Paulus W, Pizzella V, Prado P, Rauchs G, Ritter P, Salvatore M, Santamaria-García H, Schirner M, Soricelli A, Taylor J, Tankisi H, Tecchio F, Teipel S, Kodamullil A, Triggiani A, Valdes-Sosa M, Valdes-Sosa P, Vecchio F, Vossel K, Yao D, Yener G, Ziemann U, Kamondi A. Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true? Clinical Neurophysiology 2025, 172: 33-50. PMID: 39978053, DOI: 10.1016/j.clinph.2025.02.256.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPathological agingAlzheimer's diseaseExpert panelAlpha rhythmAD patient’s qualityQuality of lifeAging-Alzheimer's AssociationCognitive impairmentCognitive declineClinical workupNeuroscience SocietyCortical circuitsAD patientsUS National InstitutesOlder adultsRoutine useSenile dementiaDecades of researchPatients' qualityClinical guidelinesOscillatory synchronizationCause of dementiaClinical applicationNIA-AADementiaCSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment
Hajós M, Pandey K, Singer A, Duong D, Bitarafan S, Shpokayte M, Malchano Z, Kern R, Lah J, Levey A, Seyfried N. CSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70051. PMID: 39935616, PMCID: PMC11812123, DOI: 10.1002/trc2.70051.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCellular lipid transportLipid transportWeeks of treatmentProteomic changesAlzheimer's diseaseCerebrospinal fluidGamma oscillationsTandem mass tag-mass spectrometryNeuroimmune functionDifferential expression analysisMyelin preservationUnbiased proteomic analysisBiological pathway analysisTreatment of ADSynaptic biologyAffected proteinsProteome modulationPhosphatidylcholine biosynthesisReduced brain volumeCSF proteome changesProtein networkSensory‐evoked gamma oscillationsExpression analysisBiochemical pathwaysBiological pathways
2024
OVERTURE Phase 2 Study time‐savings analysis using composite measures of function and cognition
Kern R, Haaland B, Nicodemus‐Johnson J, Dickson S, Kuang Z, Houser C, Hajos M, Vaughan B, Hendrix S. OVERTURE Phase 2 Study time‐savings analysis using composite measures of function and cognition. Alzheimer's & Dementia 2024, 20: e094669. PMCID: PMC11712459, DOI: 10.1002/alz.094669.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsADCS-ADLSham treatmentMeasures of functionIndividual patient changesComposite measureMild-moderate Alzheimer's diseaseAt-homeMild-moderate ADTreatment effectsBaseline measurementsAlzheimer's diseaseEstimated time savingsPatients changesOne-hourMMSEPost-hocActive treatmentOutcomesTrialsBaselineAdverse eventsADLOVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis
Kern R, Kuang C, Seshagiri C, Konisky A, Galley A, Boasso A, Hempel E, Malchano Z, Vaughan B, Cimenser A, Da X, Shpokayte M, Hajos M. OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis. Alzheimer's & Dementia 2024, 20: e085091. PMCID: PMC11714597, DOI: 10.1002/alz.085091.Peer-Reviewed Original ResearchConceptsRandomized Controlled TrialsAPOE4 carrier statusBaseline subgroupsMild-moderate Alzheimer's diseasePhase 2 clinical trialIndicators of neurodegenerationBrain atrophyBrain volume outcomesBaseline ageBrain volume lossWhole brain volume lossCarrier statusWBVMagnetic resonance imagingAlzheimer's diseaseBaseline covariatesMonth 6Subgroup analysisAt-homeParticipantsClinical trialsTreatment outcomesActive treatmentOne-hourSham treatmentOVERTURE Phase 2 MRI Analysis Demonstrates Reduced Corpus Callosum Atrophy in Alzheimer's Disease
Da X, Hempel E, Hajos M, Kern R, Cimenser A. OVERTURE Phase 2 MRI Analysis Demonstrates Reduced Corpus Callosum Atrophy in Alzheimer's Disease. Alzheimer's & Dementia 2024, 20: e085446. PMCID: PMC11714734, DOI: 10.1002/alz.085446.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMonth 3Midsagittal planeDiffusion tensor imagingPhase 3 clinical trialsRegional structural alterationsCorpus callosumT1w MRI imagesMonths of treatmentCommissural white matter tractsCorpus callosum atrophyWhite matter atrophyAlzheimer's diseaseSensory stimulationMonth 6CC atrophyClinical trialsSham groupWhite matter tractsGamma frequenciesVisual stimulationResonance imaging
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link